Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population

Peritoneal Dialysis International

Volumn 25, Issue 5, 2005, Pages 473-477

  Mahajan, Sandeep ^a   Tiwari, Suresh C ^a   Kalra, Vikram ^a   Bhowmik, Dipankar M ^a   Agarwal, Sanjay K ^a   Dash, Suresh C ^a   Kumar, Parveen ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Directorate of Health Services   (India)

Author keywords

Exit site infection; Gram negative peritonitis; Indian population; Infective complications; Mupirocin; Peritonitis; Staphylococcus aureus; Tropical country

Indexed keywords

POVIDONE IODINE; PSEUDOMONIC ACID;

ADULT; AGED; ARTICLE; BACTERIAL PERITONITIS; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; INDIAN; INFECTION PREVENTION; KIDNEY FAILURE; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

EID: 26844469023     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500512     Document Type: Article

References (22)

1. United States Renal Data System. USRDS 1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
2. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7:198-207.
3. Zimmerman SW, O'Brien M, Wiedenhoeft F, Johnson C. Staphylococcus aureus peritoneal catheter-related infections: a cause of catheter loss and peritonitis. Perit Dial Int 1988; 8:191-4.
4. Turner K, Uttley L, Scrimgeour A, Mckewan A, Gokal R. Natural history of Staphylococcalaureus nasal carriage and its relationship to exit site infection. Perit Dial Int 1998; 18:271-3.
5. Chain EB, Mellows G. Pseudomonic acid. Part 1. The structure of pseudomonic acid A: a novel antibiotic produced by Pseudomonos fluorescens. J Chem Soc (Perkin) 1977; 1:294-309.
6. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Fernandez-Rivera C, Cao M, et al. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992; 8:242-5.
7. Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit site infection during peritoneal dialysis. Mupirocin Study Group. J Am Soc Nephrol 1996; 7:2403-8.
8. Davey P, Craig AM, Hau C, Malek M. Cost effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomised, placebo-controlled trial. J Antimicrob Chemother 1999; 43:105-12.
9. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27:695-700.
10. Thodis E, Bhaskaran S, Pasadakis P, Bargman JM, Vas S, Oreopoulos DG. Decrease in Staphylococcus aureus exit site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18:261.
11. Casey M, Taylor J, Clinard P, Graham A, Mauck V, Spainhour L, et al. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20:566-8.
12. Gokal R, Alexander S, Ash S, Chen TW, Danielson A, Holmes C, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. Perit Dial Int 1998; 18:11-33.
13. Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21:554-9.
14. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337-41.
15. Keane WF, Baillie GR, Boeschoten E, Gokal R, Golper TA, Homes CJ, et al. Adult peritonitis treatment recommendations: 2000 update [Published erratum appears in Perit Dial Int 2000; 20:828-9]. Perit Dial Int 2000; 20:396-411.
16. Annigeri RA, Prakash GK, Balasubramanium R, Balasubramanium S, Prakash KC, Kavitha MK. 'O'Set connector system in CAPD. J Assoc Physician India 1996; 44: 602-5.
17. Dryden MS, Ludlam HA, Wing DJ, Philips I. Active intervention dramatically reduces CAPD-associated infection. Adv Perit Dial 1991; 7:125-8.
18. Ritzau J, Hoffman RM, Tzamaloukas AH. Effect of preventing staphylococcus infections on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis. Perit Dial Int 2001; 21:471-9.
19. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EMC. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta analysis. Clin Infect Dis 2003; 37:1629-38.
20. Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Perit Dial Int 2003; 23: 456-9.
21. Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Cormona A, Adeva M, Rodriguez-Lozano I, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993; 22:708-12.
22. Conly MJ, Vas S. Increasing mupirocin resistance of Staphylococcus aureus in CAPD - should it continue to be used as prophylaxis? Perit Dial Int 2002; 22:649-52.